ZILRETTA Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Zilretta, and when can generic versions of Zilretta launch?
Zilretta is a drug marketed by Pacira Pharms Inc and is included in one NDA. There are two patents protecting this drug.
This drug has fifty-one patent family members in twenty-two countries.
The generic ingredient in ZILRETTA is triamcinolone acetonide. There are fifty-one drug master file entries for this compound. Seventy-three suppliers are listed for this compound. Additional details are available on the triamcinolone acetonide profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Zilretta
A generic version of ZILRETTA was approved as triamcinolone acetonide by TARO on October 1st, 1986.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for ZILRETTA?
- What are the global sales for ZILRETTA?
- What is Average Wholesale Price for ZILRETTA?
Summary for ZILRETTA
| International Patents: | 51 |
| US Patents: | 2 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 82 |
| Clinical Trials: | 17 |
| Patent Applications: | 4,313 |
| Drug Prices: | Drug price information for ZILRETTA |
| What excipients (inactive ingredients) are in ZILRETTA? | ZILRETTA excipients list |
| DailyMed Link: | ZILRETTA at DailyMed |
Recent Clinical Trials for ZILRETTA
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Ohio State University | Phase 4 |
| Sorrento Therapeutics, Inc. | Phase 2 |
| ROC Foundation | Phase 4 |
US Patents and Regulatory Information for ZILRETTA
ZILRETTA is protected by two US patents.
Patents protecting ZILRETTA
Corticosteroids for the treatment of joint pain
Patent Number: ⤷ Subscribe
Patent Expiration: ⤷ Subscribe
Corticosteroids for the treatment of joint pain
Patent Number: ⤷ Subscribe
Patent Expiration: ⤷ Subscribe
Patented Use: METHOD OF TREATING PAIN OR INFLAMMATION WITH AN INJECTABLE CONTROLLED OR SUSTAINED RELEASE FORMULATION OF TRIAMCINOLONE ACETONIDE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pacira Pharms Inc | ZILRETTA | triamcinolone acetonide | FOR SUSPENSION, EXTENDED RELEASE;INTRA-ARTICULAR | 208845-001 | Oct 6, 2017 | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | ||||
| Pacira Pharms Inc | ZILRETTA | triamcinolone acetonide | FOR SUSPENSION, EXTENDED RELEASE;INTRA-ARTICULAR | 208845-001 | Oct 6, 2017 | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | Y | ⤷ Subscribe | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for ZILRETTA
See the table below for patents covering ZILRETTA around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| World Intellectual Property Organization (WIPO) | 2012019009 | ⤷ Subscribe | |
| Canada | 2843139 | CORTICOSTEROIDES DESTINES A TRAITER UNE DOULEUR ARTICULAIRE (CORTICOSTEROIDS FOR THE TREATMENT OF JOINT PAIN) | ⤷ Subscribe |
| Taiwan | I630001 | ⤷ Subscribe | |
| Canada | 2956556 | CORTICOSTEROIDES POUR LE TRAITEMENT DE LA DOULEUR ARTICULAIRE (CORTICOSTEROIDS FOR THE TREATMENT OF JOINT PAIN) | ⤷ Subscribe |
| European Patent Office | 2739287 | CORTICOSTÉROÏDES DESTINÉS À TRAITER UNE DOULEUR ARTICULAIRE (CORTICOSTEROIDS FOR THE TREATMENT OF JOINT PAIN) | ⤷ Subscribe |
| Canada | 2807150 | CORTICOSTEROIDES POUR LE TRAITEMENT DE LA DOULEUR ARTICULAIRE (CORTICOSTEROIDS FOR THE TREATMENT OF JOINT PAIN) | ⤷ Subscribe |
| Singapore | 10201602789X | CORTICOSTEROIDS FOR THE TREATMENT OF JOINT PAIN | ⤷ Subscribe |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
